Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.53 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10282601 | 0.86 | GLA (0.64) | MAPK14MAPK11HSPB1CYP2C9RAB9A | |
| SCHEMBL13068954 | 0.84 | MAPK1 (0.47) | MAPK14RAB9ASMYD3KMT2AKDR | |
| SCHEMBL2948427 | 0.83 | MAPK14 (0.58) | MAPK14MAPK11HSPB1CYP2C9RAB9A | |
| SCHEMBL178451 | 0.82 | HDAC1 (0.63) | MAPK14MAPK11HSPB1CYP2C9RAB9A | |
| SCHEMBL2974767 | 0.82 | MAPK14 (0.57) | MAPK14MAPK11HSPB1CYP2C9RAB9A | |
| SCHEMBL178414 | 0.82 | MAPK14 (0.60) | MAPK14MAPK11HSPB1CYP2C9RAB9A | |
| SCHEMBL178563 | 0.82 | MEN1 (0.68) | MAPK14MAPK11HSPB1CYP2C9RAB9A | |
| SCHEMBL11965675 | 0.81 | MAPK14 (0.61) | MAPK14MAPK11HSPB1CYP2C9 | |
| SCHEMBL12217594 | 0.81 | RAB9A (0.62) | CYP2C9RAB9ANPC1HPGDCYP1A2 | |
| SCHEMBL13146407 | 0.81 | MAPK14 (0.56) | MAPK14MAPK11HSPB1CYP2C9RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385041-B1 | Pyrazole-amine compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8080546-B2 | Pyrazolo-pyridinone derivatives and methods of use | AMGEN INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2385041-A1 | Pyrazole-amine compounds useful as kinase inhibitors | Bristol-Myers Squibb Company (US) | 2011-11-09 | — | — | EP | disclosed |
| US-8041794-B2 | Platform discovery, asset inventory, configuration, and provisioning in a pre-boot environment using web services | INTEL CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-7592338-B2 | Pyrazole-amine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| US-20090137582-A1 | Pyrazolo-pyridinone derivatives and methods of use | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009055033-A1 | PYRAZOLO-PYRIDINONE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| EP-1620108-A4 | PYRAZOLE-AMINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20080004278-A1 | (1-phenyl-5-propyl-1H-pyrazol-4-yl)-(3-amino-N-cyclopropyl-4-methyl-benzamide)-amine; p38 mitogen-activated protein kinase inhibitor; reduced levels of TNF- alpha expression; antiinfammatory agent: rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-03 | — | — | US | disclosed |
| US-7253170-B2 | Pyrazole-amine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-07 | — | — | US | disclosed |
| US-7151113-B2 | Pyrazole-amine compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060247247-A1 | Pyrazole-amine compounds useful as kinase inhibitors | DYCKMAN ALARIC J | 2006-11-02 | — | — | US | disclosed |
| EP-1620108-A2 | PYRAZOLE-AMINE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20040248853-A1 | Pyrazole-amine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-09 | — | — | US | disclosed |
| WO-2004098528-A2 | PYRAZOLE-AMINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248853-A1 | Pyrazole-amine compounds useful as kinase inhibitors | MAPK1, MAP3K1, MAP3K5 | MAPK14 57/4885MAPK11 55/4885HSPB1 1779/4885 |
| US-20090137582-A1 | Pyrazolo-pyridinone derivatives and methods of use | IL1B, IL1R1, IL1A | MAPK14 52/4885MAPK11 177/4885HSPB1 1721/4885 |
| US-20080004278-A1 | (1-phenyl-5-propyl-1H-pyrazol-4-yl)-(3-amino-N-cyclopropyl-4-methyl-benzamide)-amine; p38 mitogen-activated protein kinase inhibitor; reduced levels of TNF- alpha expression; antiinfammatory agent: rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease | MAPK1, MAPK3, MAPK4 | MAPK14 11/4885MAPK11 28/4885HSPB1 491/4885 |
| US-20060247247-A1 | Pyrazole-amine compounds useful as kinase inhibitors | MAP3K1, MAP3K20, MAP3K5 | MAPK14 56/4885MAPK11 48/4885HSPB1 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.